Pre-made Concizumab benchmark antibody ( Whole mAb, anti-TFPI therapeutic antibody, Anti-EPI/LACI/TFI Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Concizumab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Concizumab (mAb 2021) is a high-affinity, humanized, monoclonal IgG4 antibody (mAb) developed by Novo Nordisk A/S. It was directed against the Kunitz-2 domain of human tissue factor (TF) pathway inhibitor (TFPI), designed to target and selectively block the factor X (FX) a (FXa) binding site of TFPI.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-118-1mg	1mg	3090
GMP-Bios-ab-118-10mg	10mg	Inquiry
GMP-Bios-ab-118-100mg	100mg	Inquiry
GMP-Bios-ab-118-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Concizumab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody
INN Name	Concizumab
Target	TFPI
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	4dtg:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Novo Nordisk
Conditions Approved	na
Conditions Active	Haemophilia
Conditions Discontinued	na
Development Tech	na